ATE362783T1 - Verwendung von dapson als neuroprotektor bei zerebralinfarkt - Google Patents

Verwendung von dapson als neuroprotektor bei zerebralinfarkt

Info

Publication number
ATE362783T1
ATE362783T1 AT04721040T AT04721040T ATE362783T1 AT E362783 T1 ATE362783 T1 AT E362783T1 AT 04721040 T AT04721040 T AT 04721040T AT 04721040 T AT04721040 T AT 04721040T AT E362783 T1 ATE362783 T1 AT E362783T1
Authority
AT
Austria
Prior art keywords
dapsone
neuroprotector
cerebral infarction
stroke
brain stroke
Prior art date
Application number
AT04721040T
Other languages
English (en)
Inventor
Castaneda Luis Camilo Rios
Martinez Marina Altagracia
Kawachi Juan Nader
Jinich J Kravzov
Original Assignee
Univ Autonoma Metropolitana
Inst Nacional De Neurologia Y
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Autonoma Metropolitana, Inst Nacional De Neurologia Y filed Critical Univ Autonoma Metropolitana
Application granted granted Critical
Publication of ATE362783T1 publication Critical patent/ATE362783T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Mobile Radio Communication Systems (AREA)
AT04721040T 2003-07-22 2004-03-16 Verwendung von dapson als neuroprotektor bei zerebralinfarkt ATE362783T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
MXPA03006549A MXPA03006549A (es) 2003-07-22 2003-07-22 Uso de la dapsona como neuroprotector en el infarto cerebral.

Publications (1)

Publication Number Publication Date
ATE362783T1 true ATE362783T1 (de) 2007-06-15

Family

ID=34075071

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04721040T ATE362783T1 (de) 2003-07-22 2004-03-16 Verwendung von dapson als neuroprotektor bei zerebralinfarkt

Country Status (15)

Country Link
US (1) US8268893B2 (de)
EP (1) EP1655055B1 (de)
JP (1) JP5452844B2 (de)
CN (1) CN100500246C (de)
AT (1) ATE362783T1 (de)
BR (1) BRPI0412212A (de)
CA (1) CA2533181C (de)
DE (1) DE602004006633T2 (de)
EA (1) EA012174B1 (de)
EC (1) ECSP066316A (de)
ES (1) ES2287713T3 (de)
HK (1) HK1098086A1 (de)
MX (1) MXPA03006549A (de)
PT (1) PT1655055E (de)
WO (1) WO2005007239A1 (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2009004635A (es) * 2009-04-29 2010-10-29 Univ Autonoma Metropolitana Formas farmaceúticas solubles de la n,n´-diamino-difenilsulfona para su uso óptimo en el tratamiento de diversas enfermedades.
KR101875705B1 (ko) * 2011-12-07 2018-07-06 삼성전자주식회사 디아미노디페닐술폰을 포함하는 근육 소모 관련 질환의 예방 또는 치료용 약학적 조성물
CN104177610A (zh) * 2013-05-27 2014-12-03 韩文毅 一种非线性的聚合物及其制备和用途
CN104177611A (zh) * 2013-05-27 2014-12-03 韩文毅 一种非线性的聚合物及其制备和用途
CN104069091A (zh) * 2014-07-09 2014-10-01 崔德华 氨苯砜在保护血脑屏障完整性中的应用
KR20160047318A (ko) * 2014-10-22 2016-05-02 삼성전자주식회사 다프손을 포함하는, 개체의 부위에서 혈관신생을 자극시키기 위한 조성물 및 그의 용도
KR20200107899A (ko) * 2019-11-16 2020-09-16 이종훈 알츠하이머병 혹은 뇌졸중의 뉴로인플라마섬의 치료제로서 디디에스 혹은 그 유도체

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5532219A (en) * 1991-04-23 1996-07-02 The University Of British Columbia Dapsone and promin for the treatment of dementia
JP2002520419A (ja) * 1998-07-15 2002-07-09 ヨマー、ハッサン リン有機化合物およびその使用
GB2362101A (en) * 2000-05-12 2001-11-14 Astrazeneca Ab Treatment of chronic obstructive pulmonary disease

Also Published As

Publication number Publication date
HK1098086A1 (en) 2007-07-13
CN100500246C (zh) 2009-06-17
EP1655055B1 (de) 2007-05-23
US20100063159A1 (en) 2010-03-11
CA2533181A1 (en) 2005-01-27
EA200600272A1 (ru) 2006-10-27
DE602004006633D1 (de) 2007-07-05
DE602004006633T2 (de) 2008-01-31
US8268893B2 (en) 2012-09-18
WO2005007239B1 (es) 2005-05-06
EP1655055A1 (de) 2006-05-10
EA012174B1 (ru) 2009-08-28
ECSP066316A (es) 2006-10-25
ES2287713T3 (es) 2007-12-16
PT1655055E (pt) 2007-08-31
JP5452844B2 (ja) 2014-03-26
CN1852749A (zh) 2006-10-25
BRPI0412212A (pt) 2006-08-22
JP2006528175A (ja) 2006-12-14
CA2533181C (en) 2012-08-07
MXPA03006549A (es) 2004-03-18
WO2005007239A1 (es) 2005-01-27

Similar Documents

Publication Publication Date Title
DE60237725D1 (de) Vervendung von dexrazoxane in der prävention und behandlung der alzeheimer-krankheit
HK1069767A1 (en) Methods for inhibiting ocular processes
ECSP066316A (es) Uso de la dapsona como neuroprotector en el infarto cerebral
EP1765388B8 (de) Kombinationstherapie zur vorbeugung oder behandlung der alzheimerschen erkrankung sowie set hierfür
WO2005113590A3 (en) Bmp10 propeptides and related methods
HRP20020593B1 (en) Brain, spinal and nerve injury treatment
DE60231804D1 (de) Verwendung von hepcidin zur herstellung eines arzneimittels zur behandlung von eisenhomöostase störungen
BR0114054A (pt) Método para tratar alergias usando pirazóis substituìdos
DE60216275D1 (de) Verwendung von mit azetidinon substituierten derivaten bei der behandlung der alzheimer-krankheit
SG149063A1 (en) Use of modified cyclosporins for the treatment of hcv disorders
DE602006008643D1 (de) Ophthalmische Zusammensetzungen von parasympathischen Stimulantia und Entzündungshemmer zur Verwendung bei der Behandlung von Presbyopie
ATE518952T1 (de) Bispezifischer antikörper als ersatz für factor viii
EA200300027A1 (ru) Способ лечения сердечно-сосудистых заболеваний
WO2001058476A3 (en) Methods and compositions for treatment of alzheimer's disease by enhancing plasmin or plasmin-like activity
DE60304695D1 (de) 7-ARYLSULFONAMID-2,3,4,5-TETRAHYDRO-1H-BENZOiDöAZEPINE MIT 5-HT6 REZEPTOR AFFINITÄT ZUR BEHANDLUNG VON ZENTRALNERVENSYSTEMERKRANKUNGEN
ATE424825T1 (de) Behandlung von hyperaktivitätsstörungen und aufmerksamkeitsdefiziten
ATE265454T1 (de) Phenyloxazol-1,4-diazabicyclo(3.2.2)nonanderiva e,ihre herstellung und ihre therapeutische verwendung
ATE556707T1 (de) Phosphodiesesterase 4 inhibitoren zur behandlung eines kognitiven defizits
HK1080408A1 (en) Use of brimonidine in the treatment of dementia a nd parkinson
ATE552251T1 (de) Thiophen- und furanverbindungen
SI1744736T1 (sl) Postopek za zdravljenje težav s suhimi očmi in uveitisa
PL376056A1 (en) 3,4-disubstituted pyrroles and their for use in treating inflammatory diseases
MXPA05002418A (es) Derivados de 1,4-pirazina sustituidos.
WO2007047323A3 (en) Methods to treat alzheimer's disease or other disorders mediated by amyloid-beta accumulation in a subject
WO2002099422A3 (en) Individualization of therapy with alzheimer's disease agents

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties